Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01130142 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer
A Phase 1 study, sponsored by Infinity Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 122
- Enrollment target
NCT01130142 is a Phase 1 study that has completed, run by Infinity Pharmaceuticals. The registered enrollment target is 122 participants.
The verdict
NCT01130142, a Phase 1 study, has completed, sponsored by Infinity Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 122 participants
- Enrollment target
Study Summary
Study IPI-926-03 is a Phase 1b/2 clinical trial to evaluate IPI 926 in combination with gemcitabine in patients with previously untreated metastatic pancreatic cancer. Phase 1b is designed as a dose escalation study. Once the maximum tolerated dose of IPI-926 in combination with gemcitabine is established in the Phase 1b portion of the study, the Phase 2 portion will commence. Phase 2 is designed as a randomized, double-blind (investigator/patient), placebo-controlled study. There is no cross-over option for patients in either arm of the Phase 2 (i.e., there is no option for patients receiving placebo to cross-over to IPI-926).
Interventions
- DRUG IPI-926 plus gemcitabine
- DRUG Placebo plus gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2010-04 |
| Est. Completion | 2012-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01130142
The ClinicalTrials.gov registry entry for NCT01130142 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Infinity Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which IPI-926 plus gemcitabine is the first listed.
NCT01130142 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01130142 about?
NCT01130142 is a clinical study titled "A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer". Study IPI-926-03 is a Phase 1b/2 clinical trial to evaluate IPI 926 in combination with gemcitabine in patients with previously untreated metastatic pancreatic cancer. Phase 1b is designed as a dose escalation study. Once the maximum tolerated dose of IPI-926 in combination with gemcitabine is estab...
What is the current status of trial NCT01130142?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 122 participants. The study started on 2010-04. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01130142?
The interventions under investigation include: IPI-926 plus gemcitabine (DRUG), Placebo plus gemcitabine (DRUG).
Who is sponsoring clinical trial NCT01130142?
This trial is sponsored by Infinity Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.